- Home
- MATX vs CDTX Comparison
MATX vs CDTX Comparison
Compare MATX & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATX
- CDTX
- Stock Information
- Founded
- MATX 1882
- CDTX 2012
- Country
- MATX United States
- CDTX United States
- Employees
- MATX N/A
- CDTX N/A
- Industry
- MATX Marine Transportation
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MATX Consumer Discretionary
- CDTX Health Care
- Exchange
- MATX Nasdaq
- CDTX Nasdaq
- Market Cap
- MATX 3.1B
- CDTX 2.8B
- IPO Year
- MATX N/A
- CDTX 2015
- Fundamental
- Price
- MATX $99.90
- CDTX $102.77
- Analyst Decision
- MATX Hold
- CDTX Strong Buy
- Analyst Count
- MATX 4
- CDTX 13
- Target Price
- MATX $131.67
- CDTX $118.50
- AVG Volume (30 Days)
- MATX 356.4K
- CDTX 938.8K
- Earning Date
- MATX 11-04-2025
- CDTX 11-06-2025
- Dividend Yield
- MATX 1.44%
- CDTX N/A
- EPS Growth
- MATX 56.13
- CDTX N/A
- EPS
- MATX 14.81
- CDTX N/A
- Revenue
- MATX $3,464,800,000.00
- CDTX N/A
- Revenue This Year
- MATX N/A
- CDTX N/A
- Revenue Next Year
- MATX $1.45
- CDTX N/A
- P/E Ratio
- MATX $6.75
- CDTX N/A
- Revenue Growth
- MATX 8.75
- CDTX N/A
- 52 Week Low
- MATX $86.97
- CDTX $12.74
- 52 Week High
- MATX $169.12
- CDTX $121.21
- Technical
- Relative Strength Index (RSI)
- MATX 55.69
- CDTX 54.83
- Support Level
- MATX $96.70
- CDTX $102.19
- Resistance Level
- MATX $100.85
- CDTX $113.00
- Average True Range (ATR)
- MATX 2.52
- CDTX 6.48
- MACD
- MATX 1.06
- CDTX -0.89
- Stochastic Oscillator
- MATX 73.86
- CDTX 47.27
About MATX Matson Inc.
Matson Inc is engaged in providing ocean transportation and logistics services. The business segments of the company are Ocean Transportation which provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific, and Logistics segment which offers long haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.